This apparent contradiction suggests that HCC patients with high levels of RRM2 could not be best suited for treatment with Sorafenib, while patients with low levels of RRM2 could succeed with the same drug [16, 17]. The gene discussed is RRM2; the disease is hepatocellular carcinoma.